“…This diversity, together with the availability of marine resources, have driven the search for new antihypertensive agents, which could be administered as functional foods or dietary supplements. Since the first discovery of a marine-derived peptide with ACE-inhibitory activity, researchers have identified a variety of antihypertensive peptides in hydrolysates from marine species, such as Synodus macrops [ 12 ] (AGPPGSDGQPGAK, IC 50 = 0.42 mM), Salmo salar [ 13 ] (GAR and IGPR, IC 50 = 0.598, 0.43 mM), shrimps (SSSKAKKMP, IC 50 = 0.88 mM) [ 14 ], and Ruditapes philippinarum (pRPH, tRPH and nRPH, IC 50 = 0.42, 2.93 and 3.53 mg/mL) [ 15 ]. Some marine-derived peptides are currently being evaluated for safety and efficacy through ongoing clinical trials which have advanced to different phases, and even a small number have entered the market.…”